EMERYVILLE, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
"This is our third issued U.S. patent covering the methods of use of controlled-release amantadine formulations, potentially extending our coverage beyond Parkinson's disease into a wider set of indications, including other movement disorders," said Gregory T. Went, PhD., Chairman and Chief Executive Officer of Adamas and a co-inventor on the patent. "We are pleased with the expansion of our patent estate, and we are continuing to pursue additional composition of matter and methods of use patents to protect a wide range of controlled-release amantadine products."
ADS-5102 and related controlled-release amantadine product candidates of ours are currently covered by three issued U.S. method of use patents that expire in 2027 and 2030 and an additional 11 U.S. patent applications. These patents and patent applications are wholly owned by Adamas and are not subject to any license agreements. Adamas also owns additional foreign patent applications covering ADS-5102.
Adamas' strategy is to discover novel pharmacokinetic and pharmacodynamic relationships and to obtain patent protection on pharmacokinetic profiles, timing of administration, dose strengths and drug combinations. Secondarily, Adamas seeks to protect specific formulations. Overall, Adamas' patent portfolio of pharmacokinetic enhancement and fixed-dose combination inventions related to its central nervous system product and product candidate portfolio now includes 15 issued U.S. patents, 12 pending U.S. patents and 18 patents granted by patent authorities outside of the U.S., and multiple pending applications.
Adamas' most advanced wholly-owned product candidate is ADS-5102 (amantadine HCl), a high dose, controlled-release version of amantadine, that is administered once daily at bedtime. Adamas is initially developing ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. LID is a movement disorder that frequently occurs in patients after long-term treatment with levodopa, the most widely used drug for Parkinson's disease. There are no approved drugs for the treatment of LID in the United States or Europe. Adamas is also evaluating ADS-5102 for additional indications.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa-induced dyskinesia (LID) and is evaluating other potential indications. The company's portfolio also includes a fixed-dose combination product candidate, MDX-8704, being developed with Forest Laboratories, Inc., a subsidiary of Actavis plc, and an approved controlled-release product Namenda XR®, which Forest developed and is marketing in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.
This press release contains "forward-looking" statements, including, without limitation, statements related to the scope of Adamas' intellectual property protection and coverage of ADS-5102. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Adamas' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Adamas' product candidates, Adamas' need for additional capital in the future to sufficiently fund its operations and research, the uncertain timing of completion of and the success of clinical trials, market competition, as well as other risks detailed from time to time in Adamas' reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. Adamas does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
CONTACT: For questions, please contact: Julie Wood Investor Relations & Corporate Communications Adamas Pharmaceuticals, Inc. Phone: 510-450-3528
Source:Adamas Pharmaceuticals, Inc.